menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

When the Drug Fits: Examining Targeted Cancer Therapy

close
When the Drug Fits: Examining Targeted Cancer Therapy
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    Imatinib mesylate was initially approved for chronic myeloid leukemia. It has also been used against gastrointestinal cancer and melanoma. What are the implications of broadening the application of this targeted cancer drug for the way that cancers are diagnosed and classified, and what will the impact be on clinical trial design? Are we getting closer to the end of tumor-typing by location?

    Series Produced in Cooperation With

    Evidence-Based MedicineEvidence-Based Medicine

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Imatinib mesylate was initially approved for chronic myeloid leukemia. It has also been used against gastrointestinal cancer and melanoma. What are the implications of broadening the application of this targeted cancer drug for the way that cancers are diagnosed and classified, and what will the impact be on clinical trial design? Are we getting closer to the end of tumor-typing by location?

    Series Produced in Cooperation With

    Evidence-Based MedicineEvidence-Based Medicine

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/29/20